Encouraging Phase 2 results for Agenus Herpes vaccine

In an 80-patient randomized double-blind Phase 2 clinical trial evaluating Agenus' (AGEN) HerpV synthetic vaccine candidate for the treatment of genital Herpes Simplex Virus-2 (HSV-2), more than half of the 70 patients who received the vaccine developed a robust anti-HSV cytotoxic T-cell immune response. In this group of patients there was a statistically significant 75% reduction in viral load. This degree of reduction can potentially reduce the incidence and severity of herpetic outbreaks and a reduction in viral transmission.

HerpV is a recombinant therapeutic vaccine based on the company's Heat Shock Protein platform. It also contains Agenus' QS-21 Stimulon, a plant-derived adjuvant that boosts specific immune responses.

AGEN shares are up 16% premarket on moderately high volume.

From other sites
Comments (1)
  • cowgoesmoo123
    , contributor
    Comment (1) | Send Message
    Amazing! I'm praying for a cure. Hopefully in the near near future.
    26 Jun 2014, 04:21 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs